|

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

RECRUITINGN/ASponsored by Severance Hospital
Actively Recruiting
PhaseN/A
SponsorSeverance Hospital
Started2013-01-01
Est. completion2030-12-31
Eligibility
Age19 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02431845

Summary

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Eligibility

Age: 19 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

1. age 19\~ 70
2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV)
3. drug naive or drug free for more than 3 months

Exclusion Criteria:

1. any neurological disorder
2. comorbid psychotic disorders
3. alcohol or other substance dependence within past 6 months
4. any evidences for brain diseases

Conditions2

AnxietyObsessive-compulsive Disorder

Browse More Trials

Anxiety trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.